Journal
PHARMACOLOGY
Volume 104, Issue 5-6, Pages 267-275Publisher
KARGER
DOI: 10.1159/000502076
Keywords
Epigallocatechin-3-gallate; Hepatocellular carcinoma; Selective EP1 receptor antagonist
Categories
Funding
- Natural Science Foundation of Colleges and Universities in Anhui Province [KJ2017A179]
Ask authors/readers for more resources
Epigallocatechin-3-gallate (EGCG), the principal catechin of green tea, modulates different molecular mechanisms underlying hepatocellular carcinoma (HCC). Accumulating studies showed that the activation of prostaglandin (PG) receptor EP1 promotes cell migration and invasion in different cancers, which could be inverted by blocking the EP1 receptor. This study investigated the synergetic effects of EP1-selective antagonist ONO-8711 and EGCG treatment on HCC to better understand the potential strategy to treat HCC. We found that EGCG significantly inhibited PGE(2) and EP1-selective agonist induced migration of HCC cells and increased the ratio of Bax/Bcl-2 even in the presence of ONO-DI-004 or PGE(2). ONO-8711 significantly inhibited PGE(2)-induced HCC proliferation while increased the inhibitory effect of EGCG on HCC cell viability and migration ability compared with EGCG alone. These findings suggest that a combination of ONO-8711 and EGCG is a potential treatment for HCC therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available